Rifampicin

availability_state

machinery_impairment Imported condition classification; unverified.

evidence_span

{"source_cache": "artifacts/mangiferin-research/16141538.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9bf5373ce89587337b6d0520b931f202d44771dba205220b8e340b9fa7446b88", "start_char": 0, "end_char": 1356, "text_sha256": "9bf5373ce89587337b6d0520b931f202d44771dba205220b8e340b9fa7446b88"}

experimental_model

Isolated anaerobic human-fecal bacterium and cell-free extracts

exposure

Mangiferin culture exposure, with transcription/translation inhibitors

limitations

One isolate; activity identity unresolved; not a prediction of every human microbiome.

nutrient_topic

Mangiferin research collection; topical membership is not evidence of a direct dietary effect. · Mangiferin

organism

Bacteroides sp. MANG

plain_language

Conversion requires functioning bacterial gene-expression machinery.

primary_references

[mangiferin-p16141538] Isolation of a human intestinal bacterium that transforms mangiferin to norathyriol and inducibility of the enzyme that cleaves a C-glucosyl bond. (2005). https://pubmed.ncbi.nlm.nih.gov/16141538/ DOI: 10.1248/bpb.28.1672

tissue_or_cell_type

Bacterial culture

trigger_kind

machinery_impairment Imported condition classification; unverified.

Mangiferin: metabolism, signaling and nutrient connections (2026-09-17) · lines 119–130

AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Isolated anaerobic human-fecal bacterium and cell-free extracts · source_derived_draft · unverified_draft

### mangiferin-rifampicin-cleavage The rifampicin treatment abolished the induced C-glucosyl-cleaving activity. Condition category: machinery_impairment nutrient_topic: Mangiferin research collection; topical membership is not evidence of a direct dietary effect. plain_language: Conversion requires functioning bacterial gene-expression machinery. organism: Bacteroides sp. MANG tissue_or_cell_type: Bacterial culture experimental_model: Isolated anaerobic human-fecal bacterium and cell-free extracts limitations: One isolate; activity identity unresolved; not a prediction of every human microbiome. exposure: Mangiferin culture exposure, with transcription/translation inhibitors evidence_span: {"source_cache": "artifacts/mangiferin-research/16141538.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9bf5373ce89587337b6d0520b931f202d44771dba205220b8e340b9fa7446b88", "start_char": 0, "end_char": 1356, "text_sha256": "9bf5373ce89587337b6d0520b931f202d44771dba205220b8e340b9fa7446b88"} [mangiferin-p16141538] Isolation of a human intestinal bacterium that transforms mangiferin to norathyriol and inducibility of the enzyme that cleaves a C-glucosyl bond. (2005). https://pubmed.ncbi.nlm.nih.gov/16141538/ DOI: 10.1248/bpb.28.1672

duration

Single dose, sampling to 24 hours

evidence_access

Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.

experimental_model

11 healthy human volunteers, randomised crossover

exposure

Two 40 mg oral atorvastatin doses one week apart, with one 30-minute intravenous infusion of 600 mg rifampicin on one of the two study days

limitations

Rifampicin is used here as a model hepatic uptake inhibitor and is not selective for OATP1B1; the lactone forms rose less than the acid, and a single intravenous dose avoids the enzyme induction that repeated oral rifampicin would cause.

organism

11 healthy human volunteers, randomised crossover

plain_language

A single intravenous dose of rifampicin increased the total plasma exposure of atorvastatin acid by 6.8-fold in healthy volunteers.

primary_references

The effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. (2007). https://pubmed.ncbi.nlm.nih.gov/17192770/ DOI: 10.1038/sj.clpt.6100038

route

Oral atorvastatin with intravenous rifampicin

tissue

Plasma atorvastatin acid and its hydroxy metabolites

OATP1B1 activity and statin exposure: the step between transporter inhibition and drug concentration (2026-09-22) · lines 13–22

Original AI-assisted curation of four primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Three of the four share one research group and are recorded as one line of evidence. Study-specific citations, doses and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

## rifampicin-raises-atorvastatin-exposure A single intravenous dose of rifampicin increased the total plasma exposure of atorvastatin acid by 6.8-fold in healthy volunteers. Model/species: 11 healthy human volunteers, randomised crossover Tissue/system: Plasma atorvastatin acid and its hydroxy metabolites Exposure: Two 40 mg oral atorvastatin doses one week apart, with one 30-minute intravenous infusion of 600 mg rifampicin on one of the two study days Route: Oral atorvastatin with intravenous rifampicin Duration: Single dose, sampling to 24 hours Limits: Rifampicin is used here as a model hepatic uptake inhibitor and is not selective for OATP1B1; the lactone forms rose less than the acid, and a single intravenous dose avoids the enzyme induction that repeated oral rifampicin would cause. Primary reference: The effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. (2007). https://pubmed.ncbi.nlm.nih.gov/17192770/ DOI: 10.1038/sj.clpt.6100038 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.

duration

Single dose in both designs

evidence_access

Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.

experimental_model

Healthy human volunteers, by pharmacological inhibition and by reduced-function genotype

exposure

Rifampicin inhibition in one study and the SLCO1B1 c.521CC genotype in another

limitations

This is the mechanistic reading shared by an inhibitor study and a genotype study rather than a single measurement of transporter activity against exposure; neither study measured OATP1B1 activity directly in the participants.

organism

Healthy human volunteers, by pharmacological inhibition and by reduced-function genotype

plain_language

OATP1B1 activity lowers plasma atorvastatin exposure by carrying the drug from portal blood into the hepatocyte, so reducing that activity raises the plasma concentration.

primary_references

The effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. (2007). https://pubmed.ncbi.nlm.nih.gov/17192770/ DOI: 10.1038/sj.clpt.6100038

route

Oral atorvastatin

tissue

Hepatic sinusoidal uptake and systemic plasma exposure

OATP1B1 activity and statin exposure: the step between transporter inhibition and drug concentration (2026-09-22) · lines 24–33

Original AI-assisted curation of four primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Three of the four share one research group and are recorded as one line of evidence. Study-specific citations, doses and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

## oatp1b1-activity-lowers-atorvastatin-exposure OATP1B1 activity lowers plasma atorvastatin exposure by carrying the drug from portal blood into the hepatocyte, so reducing that activity raises the plasma concentration. Model/species: Healthy human volunteers, by pharmacological inhibition and by reduced-function genotype Tissue/system: Hepatic sinusoidal uptake and systemic plasma exposure Exposure: Rifampicin inhibition in one study and the SLCO1B1 c.521CC genotype in another Route: Oral atorvastatin Duration: Single dose in both designs Limits: This is the mechanistic reading shared by an inhibitor study and a genotype study rather than a single measurement of transporter activity against exposure; neither study measured OATP1B1 activity directly in the participants. Primary reference: The effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. (2007). https://pubmed.ncbi.nlm.nih.gov/17192770/ DOI: 10.1038/sj.clpt.6100038 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.